• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

PSA doubling time predicts prostate cancer recurrence

Article

PSA doubling time appears to be a reliable tool to distinguish which patients have prolonged innocuous PSA levels after therapy from those who are at great risk for disease recurrence and death from prostate cancer, according to researchers from the Mayo Clinic in Rochester, MN.

PSA doubling time appears to be a reliable tool to distinguish which patients have prolonged innocuous PSA levels after therapy from those who are at great risk for disease recurrence and death from prostate cancer, according to researchers from the Mayo Clinic in Rochester, MN.

In a study of more than 1,000 patients with a calculable PSA doubling time, patients with a PSA doubling time of less than 3 months after therapy are at imminent risk of death from prostate cancer. Patients with a doubling time of 3 to 12 months are at a significant risk for the development of systematic disease and cancer-specific death, Michael Blute, MD, and colleagues reported in Mayo Clinic Proceedings (2007; 82:422-7).

According to Dr. Blute, the new findings should prompt physicians whose patients have doubling times of less than 1 year to treat them with systematic therapies. Patients with PSA doubling times of 1 to 10 years are more likely to have a local rather than systematic recurrence, and patients with a PSA doubling time of more than 10 years are at a low risk of recurrence.

Related Videos
Neal Shore, MD, FACS, and Brian M. Shuch, MD, experts on kidney cancer
Neal Shore, MD, FACS, and Brian M. Shuch, MD, experts on kidney cancer
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
DNA helix | Image Credit: © Siarhei - stock.adobe.com
Jenny Guo, MD, answers a question during a Zoom video interview
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Related Content
© 2024 MJH Life Sciences

All rights reserved.